Concept
GLP-1 receptor agonists
5 studies
GLP-1 receptor agonists are drugs that activate the glucagon-like peptide-1 receptor to increase glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite—used mainly in type 2 diabetes and obesity, with expanding off-label and safety questions.
Students often treat “GLP-1 drugs” as one claim. Dual GIP/GLP-1 agonists vs GLP-1 RAs, efficacy as insulin add-on, pancreatitis safety signals, and neuropsychiatric repurposing answer different questions with different designs.
Studies
5
Findings
5
5 supporting · 0 challenging · 6 qualifying citations
Open tensions
2
Currently
What we know
- GLP-1RAs can be studied as add-on therapy to insulin in type 1 diabetes.
- Different GLP-1RAs have been linked to acute pancreatitis in pharmacovigilance-style case series.
- Semaglutide/liraglutide are being explored beyond glycemic control (e.g., alcohol use disorder).
- In US EHR data, starting tirzepatide associated with fewer deaths and CV/kidney events than starting a GLP-1 RA.
- FAERS biliary signals were clearer for DPP-4 inhibitors than for GLP-1 RAs as a class, with agent exceptions.
Largest unresolved question
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Common misconceptions
All GLP-1 drugs have identical safety and efficacy profiles.
Agent, dose, indication, and study design differ; class talk is a starting map, not a result.
A pancreatitis case series measures how common pancreatitis is on GLP-1RAs.
Case series and spontaneous reports cannot estimate incidence without denominators and controls.
Tirzepatide’s lower observational mortality than GLP-1 RAs proves it is safer in every patient.
The association comes from matched US records with short follow-up; residual confounding remains, and it does not replace safety signals or trial evidence for other indications.
Related
Claim ledger
What the evidence shows
Drawn from 5 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
GLP-1RAs can be studied as add-on therapy to insulin in type 1 diabetes.
A systematic/clinical synthesis evaluates glucagon-like peptide-1 receptor agonists added to insulin for type 1 diabetes—glucose and weight outcomes under insulin co-therapy.
- Do GLP-1 drugs show pancreatitis safety signals?— pancreatitis case series ≠ T1D efficacy trial
Study Role Design N Population Outcome Do GLP-1 drugs help as add-ons in type 1 diabetes? Supports Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events Do GLP-1 drugs show pancreatitis safety signals? Qualifiespancreatitis case series ≠ T1D efficacy trial OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents Different GLP-1RAs have been linked to acute pancreatitis in pharmacovigilance-style case series.
A case-series analysis associates specific GLP-1 receptor agonists with acute pancreatitis reports—useful for safety signal literacy, not incidence rates.
- Do GLP-1 drugs help as add-ons in type 1 diabetes?— efficacy add-on ≠ spontaneous pancreatitis reports
Study Role Design N Population Outcome Do GLP-1 drugs show pancreatitis safety signals? Supports OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents Do GLP-1 drugs help as add-ons in type 1 diabetes? Qualifiesefficacy add-on ≠ spontaneous pancreatitis reports Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events Semaglutide/liraglutide are being explored beyond glycemic control (e.g., alcohol use disorder).
Repurposing work examines semaglutide and liraglutide for alcohol use disorder—illustrating that receptor class claims travel across indications carefully.
In US EHR data, starting tirzepatide associated with fewer deaths and CV/kidney events than starting a GLP-1 RA.
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
- Do GLP-1 drugs show pancreatitis safety signals?— spontaneous pancreatitis case series cannot estimate comparative mortality in T2D initiators
- Do GLP-1 drugs help as add-ons in type 1 diabetes?— T1D insulin add-on synthesis ≠ T2D dual-agonist vs GLP-1 RA comparative cohort
Study Role Design N Population Outcome Is tirzepatide linked to fewer deaths than GLP-1 drugs? Supports CohortRetrospective TriNetX cohort of US adults with type 2 diabetes initiating tirzepatide vs GLP-1 RA (June 2022–June 2023), with 1:1 propensity-score matching N=140308 · 140,308 patients: 14,834 tirzepatide and 125,474 GLP-1 RA before matching; median follow-up 10.5 months US adults ≥18 years with type 2 diabetes starting tirzepatide or a GLP-1 RA, without baseline stage 5 CKD/kidney failure or recent MI/stroke All-cause mortality (primary); MACEs, kidney events, AKI, and major adverse kidney events Do GLP-1 drugs show pancreatitis safety signals? Qualifiesspontaneous pancreatitis case series cannot estimate comparative mortality in T2D initiators OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents Do GLP-1 drugs help as add-ons in type 1 diabetes? QualifiesT1D insulin add-on synthesis ≠ T2D dual-agonist vs GLP-1 RA comparative cohort Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events FAERS biliary signals were clearer for DPP-4 inhibitors than for GLP-1 RAs as a class, with agent exceptions.
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46). Overall GLP-1 RAs were called non-significant (ROR 1.60), but semaglutide (4.06) and liraglutide (3.88) signaled; serious outcomes were 76.88% of DPP-4 vs 51.55% of GLP-1 reports.
- Do GLP-1 drugs show pancreatitis safety signals?— pancreatitis ICSRs ≠ biliary-disorder RORs; both lack incidence denominators
- Is tirzepatide linked to fewer deaths than GLP-1 drugs?— matched T2D EHR mortality/CV outcomes ≠ spontaneous biliary reporting ratios
Study Role Design N Population Outcome Do incretin drugs flag biliary harm in FAERS? Supports OtherFAERS/OpenVigil 2.1 disproportionality (ROR, PRR, BCPNN, EBGM) of GLP-1 RAs and DPP-4 inhibitors vs biliary SMQs, Q1 2013–Q1 2024 N=2215 · 2,215 biliary adverse-event reports (1,709 GLP-1 RA; 506 DPP-4 inhibitor) with the drug as primary suspect Spontaneous FAERS reports for six GLP-1 RAs and four DPP-4 inhibitors, 2013 Q1–2024 Q1 Reporting odds ratios and serious-outcome fractions for biliary SMQ subgroups including gallstones and biliary malignancy Do GLP-1 drugs show pancreatitis safety signals? Qualifiespancreatitis ICSRs ≠ biliary-disorder RORs; both lack incidence denominators OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents Is tirzepatide linked to fewer deaths than GLP-1 drugs? Qualifiesmatched T2D EHR mortality/CV outcomes ≠ spontaneous biliary reporting ratios CohortRetrospective TriNetX cohort of US adults with type 2 diabetes initiating tirzepatide vs GLP-1 RA (June 2022–June 2023), with 1:1 propensity-score matching N=140308 · 140,308 patients: 14,834 tirzepatide and 125,474 GLP-1 RA before matching; median follow-up 10.5 months US adults ≥18 years with type 2 diabetes starting tirzepatide or a GLP-1 RA, without baseline stage 5 CKD/kidney failure or recent MI/stroke All-cause mortality (primary); MACEs, kidney events, AKI, and major adverse kidney events
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Study Role Design N Population Outcome Do GLP-1 drugs help as add-ons in type 1 diabetes? Supports Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events Do GLP-1 drugs show pancreatitis safety signals? Supports OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents
Qualified studies asking the same question reach different answers. The disagreement is listed, not scored.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
- Is tirzepatide linked to fewer deaths than GLP-1 drugs?
- Do GLP-1 drugs show pancreatitis safety signals?
- Do GLP-1 drugs help as add-ons in type 1 diabetes?
- Do incretin drugs flag biliary harm in FAERS?
Study Role Design N Population Outcome Is tirzepatide linked to fewer deaths than GLP-1 drugs? Supports CohortRetrospective TriNetX cohort of US adults with type 2 diabetes initiating tirzepatide vs GLP-1 RA (June 2022–June 2023), with 1:1 propensity-score matching N=140308 · 140,308 patients: 14,834 tirzepatide and 125,474 GLP-1 RA before matching; median follow-up 10.5 months US adults ≥18 years with type 2 diabetes starting tirzepatide or a GLP-1 RA, without baseline stage 5 CKD/kidney failure or recent MI/stroke All-cause mortality (primary); MACEs, kidney events, AKI, and major adverse kidney events Do GLP-1 drugs show pancreatitis safety signals? Supports OtherCase series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events FAERS reports and case-series patients with AP while on GLP-1 RAs Disproportionality signals for acute pancreatitis across GLP-1 RA agents Do GLP-1 drugs help as add-ons in type 1 diabetes? Supports Meta-analysis / systematic reviewRandom-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D N=2856 · 11 trials; 2,856 participants from 1,379 screened records Adults with type 1 diabetes on insulin Change in HbA1c plus weight, BP, insulin doses, and selected adverse events Do incretin drugs flag biliary harm in FAERS? Supports OtherFAERS/OpenVigil 2.1 disproportionality (ROR, PRR, BCPNN, EBGM) of GLP-1 RAs and DPP-4 inhibitors vs biliary SMQs, Q1 2013–Q1 2024 N=2215 · 2,215 biliary adverse-event reports (1,709 GLP-1 RA; 506 DPP-4 inhibitor) with the drug as primary suspect Spontaneous FAERS reports for six GLP-1 RAs and four DPP-4 inhibitors, 2013 Q1–2024 Q1 Reporting odds ratios and serious-outcome fractions for biliary SMQ subgroups including gallstones and biliary malignancy
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
GLP-1 receptor agonists
Added a misconception
Tirzepatide’s lower observational mortality than GLP-1 RAs proves it is safer in every patient.
- Added a scope qualifier
Do GLP-1 drugs show pancreatitis safety signals?
- Added a scope qualifier
Do GLP-1 drugs help as add-ons in type 1 diabetes?
- Added a supporting study
Is tirzepatide linked to fewer deaths than GLP-1 drugs?
- Added a supporting study
Do GLP-1 drugs show pancreatitis safety signals?
- Added a supporting study
Is tirzepatide linked to fewer deaths than GLP-1 drugs?
- Added a supporting study
Do GLP-1 drugs help as add-ons in type 1 diabetes?
New claim
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
New tension
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
- Added a scope qualifier
Do GLP-1 drugs show pancreatitis safety signals?
- Added a scope qualifier
Is tirzepatide linked to fewer deaths than GLP-1 drugs?
- Added a supporting study
Do incretin drugs flag biliary harm in FAERS?
- Added a supporting study
Do incretin drugs flag biliary harm in FAERS?
New claim
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46). Overall GLP-1 RAs were called non-significant (ROR 1.60), but semaglutide (4.06) and liraglutide (3.88) signaled; serious outcomes were 76.88% of DPP-4 vs 51.55% of GLP-1 reports.
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46). Overall GLP-1 RAs were called non-significant (ROR 1.60), but semaglutide (4.06) and liraglutide (3.88) signaled; serious outcomes were 76.88% of DPP-4 vs 51.55% of GLP-1 reports.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: Do incretin drugs flag biliary harm in FAERS?
- Coverage updated · Added a scope qualifier: Do GLP-1 drugs show pancreatitis safety signals?
- Coverage updated · Added a scope qualifier: Is tirzepatide linked to fewer deaths than GLP-1 drugs?
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
- Coverage updated · Added a supporting study: Do incretin drugs flag biliary harm in FAERS?
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: Is tirzepatide linked to fewer deaths than GLP-1 drugs?
- Coverage updated · Added a scope qualifier: Do GLP-1 drugs show pancreatitis safety signals?
- Coverage updated · Added a scope qualifier: Do GLP-1 drugs help as add-ons in type 1 diabetes?
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
- Coverage updated · New tension
- Coverage updated · Added a supporting study: Do GLP-1 drugs show pancreatitis safety signals?
- Coverage updated · Added a supporting study: Is tirzepatide linked to fewer deaths than GLP-1 drugs?
- Coverage updated · Added a supporting study: Do GLP-1 drugs help as add-ons in type 1 diabetes?
Tirzepatide’s lower observational mortality than GLP-1 RAs proves it is safer in every patient.
- Coverage updated · Added a misconception
- Coverage updated · Concept page published
Papers
5 studies in this library bear on GLP-1 receptor agonists, ordered by citations.
- Is tirzepatide linked to fewer deaths than GLP-1 drugs?
In 140,308 US adults with type 2 diabetes, tirzepatide was associated with lower all-cause mortality (AHR 0.58) and fewer major cardiovascular and kidney events than GLP-1 receptor agonists.
- Do GLP-1 drugs lower AUD hospitalizations?
In 227,866 Swedes with AUD, semaglutide (aHR 0.64) and liraglutide (aHR 0.72) use periods had lower AUD hospitalization risk than nonuse—stronger than approved AUD meds overall.
- Do GLP-1 drugs help as add-ons in type 1 diabetes?
Across 11 RCTs (2,856 adults), GLP-1 RA add-on therapy modestly lowered HbA1c (−0.21%), weight (−4.04 kg), and insulin doses without more severe hypo/DKA, but GI adverse events rose (OR 2.96).
- Do GLP-1 drugs show pancreatitis safety signals?
Across 6,751 FAERS ICSRs (plus 39 case-series patients), AP reporting signals appeared for all studied GLP-1 RAs, especially exenatide and liraglutide.
- Do incretin drugs flag biliary harm in FAERS?
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46); overall GLP-1 RAs were called non-significant (ROR 1.60) but semaglutide (4.06) and liraglutide (3.88) signaled.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Ask PaperFren about GLP-1 receptor agonists
Study this conceptflashcards and short-answer questions
What does a GLP-1RA primarily activate?
The glucagon-like peptide-1 receptor (incretin pathway).
Why can’t a case series alone prove pancreatitis incidence?
It lacks a defined denominator/control comparison for rates.
Why is a matched EHR comparison of tirzepatide vs GLP-1 RAs not proof that dual agonists cause fewer deaths?
Observational matching cannot fully remove confounding (who gets which drug, adherence, unmeasured severity); follow-up was short and the sample is US EHR, not a randomized mortality trial.
Flashcards
0 of 8 answers reviewed